BioSpace News Archive

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33 rd Annual ROTH Conference, which will be held virtually on March 15-17, 2021.

CytRx Corporation has announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April 1, 2021.

Preceptis Medical, Inc ., a company dedicated to helping ENT surgeons improve how they care for children, today announced positive results from a prospective, multicenter study designed to assess in-office pediatric ear tube

Neurescue, a clinical-stage medical device company bringing to market the world’s first computer-aided balloon catheter for aortic occlusion, today announced that medical device industry veteran Mette-Marie Harild has been appointed to the Neurescue board of directors.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and twelve months ended December 31, 2020.

Lexicon Pharmaceuticals, Inc., will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported fourth quarter and full year 2020 financial results and provided a business update.

ViewRay, Inc. announced financial results for the fourth quarter and year ended December 31, 2020.

Evofem Biosciences, Inc., a commercial stage biopharmaceutical company, reported financial results for the three- and twelve-month periods ended December 31, 2020.

Prometheus Biosciences, Inc., a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease, announced the appointment of commercial veteran Mark Stenhouse as Chief Operating Officer.